ADMA Biologics Announces FDA Approval for Bivigam in the Pediatric Patient Setting for Those 2 Years of Age and Older
Signifies the Successful Fulfillment of Bivigam’s Post Marketing Commitments as Part of the Original BLA Approval
Expanded Label in the U.S. Now Includes Pediatric PI Patients 2 Years of Age and Older
RAMSEY, N.J. and BOCA RATON, Fla.,...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news